Amyloid beta as a regulator of lipid homeostasis

Trends in Molecular Medicine

Volumn 13, Issue 8, 2007, Pages 337-344

  Grimm, Marcus O W ^a   Grimm, Heike S ^a   Hartmann, Tobias ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA N ACETYLHEXOSAMINIDASE; BETA N ACETYLHEXOSAMINIDASE A; BETA SECRETASE; CERAMIDE; CEREBROSIDE SULFATASE; GALACTOSYLCERAMIDE; GAMMA SECRETASE; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GLOBOTRIAOSYLCERAMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; PSYCHOSINE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STERYL SULFATASE; SULFATIDE; TETRASPANIN;

ALZHEIMER DISEASE; CHOLESTEROL SYNTHESIS; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; FABRY DISEASE; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; GM1 GANGLIOSIDOSIS; GM2 GANGLIOSIDOSIS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; LIPID RAFT; METACHROMATIC LEUKODYSTROPHY; MULTIPLE SULFATASE DEFICIENCY; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SANDHOFF DISEASE; TAY SACHS DISEASE; TRANSCRIPTION INITIATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHOLESTEROL; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MEMBRANE MICRODOMAINS;

EID: 34547145226     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.06.004     Document Type: Review

References (93)

1. Brookmeyer R., et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88 (1998) 1337-1342
2. Wilquet V., and De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr. Opin. Neurobiol. 14 (2004) 582-588
3. Kuo Y.M., et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271 (1996) 4077-4081
4. De Strooper B., and Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113 (2000) 1857-1870
5. Jarrett J.T., et al. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
6. Heber S., et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J. Neurosci. 20 (2000) 7951-7963
7. Wang P., et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J. Neurosci. 25 (2005) 1219-1225
8. Herms J., et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 23 (2004) 4106-4115
9. Tissir F., and Goffinet A.M. Reelin and brain development. Nat. Rev. Neurosci. 4 (2003) 496-505
10. Senechal Y., et al. Amyloid precursor protein knockdown by siRNA impairs spontaneous alteration in adult mice. J. Neurochem. (2007) 10.1111/j.1471-4159.2007.04672.x
11. Ho A., and Sudhof T.C. Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2548-2553
12. Waldron E., et al. Functional role of the low-density lipoprotein receptor-related protein in Alzheimer's disease. Neurodegener. Dis. 3 (2006) 233-238
13. Soba P., et al. Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 24 (2005) 3624-3634
14. Small D.H., et al. Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. J. Alzheimers Dis. 1 (1999) 275-285
15. Wolf G., et al. PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. J. Biol. Chem. 270 (1995) 27407-27410
16. King G.D., et al. X11alpha modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the YENPTY sequence. Neuroscience 120 (2003) 143-154
17. Noviello C., et al. Autosomal recessive hypercholesterolemia protein interacts with and regulates the cell surface level of Alzheimer's amyloid beta precursor protein. J. Biol. Chem. 278 (2003) 31843-31847
18. Santolini E., et al. Numb is an endocytic protein. J. Cell Biol. 151 (2000) 1345-1352
19. Mishra S.K., et al. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J. 21 (2002) 4915-4926
20. Ogawa M., et al. The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron 14 (1995) 899-912
21. Homayouni R., et al. Disabled-1 binds to the cytoplasmic domain of amyloid precursor-like protein 1. J. Neurosci. 19 (1999) 7507-7515
22. Inomata H., et al. A scaffold protein JIP-1b enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1. J. Biol. Chem. 278 (2003) 22946-22955
23. Taru H., et al. Interaction of Alzheimer's beta -amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade. J. Biol. Chem. 277 (2002) 20070-20078
24. Tarr P.E., et al. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc. J. Biol. Chem. 277 (2002) 16798-16804
25. Nishimoto I., et al. Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). Nature 362 (1993) 75-79
26. von Rotz R.C., et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 117 (2004) 4435-4448
27. Baek S.H., et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110 (2002) 55-67
28. Kim H.S., et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. FASEB J. 17 (2003) 1951-1953
29. Pardossi-Piquard R., et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46 (2005) 541-554
30. Hebert S.S., et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 7 (2006) 739-745
31. Turner P.R., et al. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70 (2003) 1-32
32. Caille I., et al. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131 (2004) 2173-2181
33. Grziwa B., et al. The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J. Biol. Chem. 278 (2003) 6803-6808
34. Hartmann T., et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat. Med. 3 (1997) 1016-1020
35. Cook D.G., et al. Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med. 3 (1997) 1021-1023
36. Lichtenthaler S.F., et al. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1365-1370
37. Grimm M.O., et al. Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol. Scand. Suppl. 185 (2006) 27-32
38. Zha Q., et al. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 9 (2004) 946-952
39. Grimm M.O., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7 (2005) 1118-1123
40. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
41. Kivipelto M., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
42. Avdulov N.A., et al. Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69 (1997) 1746-1752
43. Fassbender K., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5856-5861
44. Refolo L.M., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 (2001) 890-899
45. Sparks D.L., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62 (2005) 753-757
46. Refolo L.M., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000) 321-331
47. Shie F.S., et al. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13 (2002) 455-459
48. Jick H., et al. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
49. Wolozin B., et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
50. Rockwood K., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59 (2002) 223-227
51. Simons M., et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52 (2002) 346-350
52. Blennow K., et al. Gangliosides in cerebrospinal fluid in 'probable Alzheimer's disease'. Arch. Neurol. 48 (1991) 1032-1035
53. Simons M., et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6460-6464
54. Wahrle S., et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9 (2002) 11-23
55. Yamazaki T., et al. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J. Biol. Chem. 276 (2001) 4454-4460
56. Puglielli L., et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3 (2001) 905-912
57. Cutler R.G., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2070-2075
58. Wood W.G., et al. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging 23 (2002) 685-694
59. Kracun I., et al. Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 20 (1992) 433-438
60. Svennerholm L., et al. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J. Neurochem. 63 (1994) 1802-1811
61. Kracun I., et al. Brain gangliosides in Alzheimer's disease. J. Hirnforsch. 31 (1990) 789-793
62. Tamboli I.Y., et al. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280 (2005) 28110-28117
63. Muniz M., et al. Protein sorting upon exit from the endoplasmic reticulum. Cell 104 (2001) 313-320
64. Matsuoka Y., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 23 (2003) 29-33
65. Cedazo-Minguez A., et al. Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem. Int. 38 (2001) 615-625
66. Fiedler K., et al. Glycosphingolipid-enriched, detergent-insoluble complexes in protein sorting in epithelial cells. Biochemistry 32 (1993) 6365-6373
67. Brown D.A., and London E. Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes?. Biochem. Biophys. Res. Commun. 240 (1997) 1-7
68. Simons K., and Vaz W.L. Model systems, lipid rafts, and cell membranes. Annu. Rev. Biophys. Biomol. Struct. 33 (2004) 269-295
69. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1 (2000) 31-39
70. Simons K., and Ikonen E. How cells handle cholesterol. Science 290 (2000) 1721-1726
71. Hakomori S., and Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 531 (2002) 88-92
72. Vetrivel K.S., et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 279 (2004) 44945-44954
73. Cordy J.M., et al. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11735-11740
74. Marlow L., et al. Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP). J. Mol. Neurosci. 20 (2003) 233-239
75. Ehehalt R., et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
76. Riddell D.R., et al. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 11 (2001) 1288-1293
77. Parkin E.T., et al. Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. Biochem. J. 344 (1999) 23-30
78. Lee S.J., et al. A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4 (1998) 730-734
79. Kojro E., et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5815-5820
80. Merrill Jr. A.H. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J. Biol. Chem. 277 (2002) 25843-25846
81. Smith E.R., et al. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol. 312 (2000) 361-373
82. Venkataraman K., and Futerman A.H. Ceramide as a second messenger: sticky solutions to sticky problems. Trends Cell Biol. 10 (2000) 408-412
83. Thevissen K., et al. Ceramide involvement in apoptosis and apoptotic diseases. Mini Rev. Med. Chem. 6 (2006) 699-709
84. Nguyen H.N., et al. Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer's disease. Arch. Pharm. Res. 29 (2006) 884-889
85. Friesen J.A., and Rodwell V.W. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol. 5 (2004) 248
86. Brown A.J., et al. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol. Cell 10 (2002) 237-245
87. Jana A., and Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J. Biol. Chem. 279 (2004) 51451-51459
88. Malaplate-Armand C., et al. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23 (2006) 178-189
89. Tschäpe J.-A., and Hartmann T. Therapeutic perspectives in Alzheimer's disease. Recent Pat. CNS Drug Discov. 1 (2006) 119-127
90. Freund-Levi Y., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63 (2006) 1402-1408
91. Oksman M., et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23 (2006) 563-572
92. Calon F., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
93. Lim G.P., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25 (2005) 3032-3040